These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 18652674)
21. Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary-mucinous tumor and invasive ductal adenocarcinoma of the pancreas. Semba S; Moriya T; Kimura W; Yamakawa M Pancreas; 2003 Apr; 26(3):250-7. PubMed ID: 12657951 [TBL] [Abstract][Full Text] [Related]
22. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma. Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758 [TBL] [Abstract][Full Text] [Related]
23. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. García-Reyes B; Kretz AL; Ruff JP; von Karstedt S; Hillenbrand A; Knippschild U; Henne-Bruns D; Lemke J Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340359 [TBL] [Abstract][Full Text] [Related]
24. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma. Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925 [TBL] [Abstract][Full Text] [Related]
25. Molecular mechanism(s) of actinomycin-D induced sensitization of pancreatic cancer cells to CD95 mediated apoptosis. Glazyrin AL; Chinni S; Alhasan S; Adsay VN; Vaitkevicius VK; Sarkar FH Int J Oncol; 2002 Jan; 20(1):201-5. PubMed ID: 11743665 [TBL] [Abstract][Full Text] [Related]
26. Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma. Igbinigie E; Guo F; Jiang SW; Kelley C; Li J Clin Chim Acta; 2019 Jan; 488():226-234. PubMed ID: 30452897 [TBL] [Abstract][Full Text] [Related]
27. Role of the phosphatidylinositol 3'-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines. Takeda A; Osaki M; Adachi K; Honjo S; Ito H Pancreas; 2004 Apr; 28(3):353-8. PubMed ID: 15084985 [TBL] [Abstract][Full Text] [Related]
28. Inhibition of renalase expression and signaling has antitumor activity in pancreatic cancer. Guo X; Hollander L; MacPherson D; Wang L; Velazquez H; Chang J; Safirstein R; Cha C; Gorelick F; Desir GV Sci Rep; 2016 Mar; 6():22996. PubMed ID: 26972355 [TBL] [Abstract][Full Text] [Related]
29. Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer. Ebrahimi S; Hosseini M; Shahidsales S; Maftouh M; Ferns GA; Ghayour-Mobarhan M; Hassanian SM; Avan A Curr Med Chem; 2017; 24(13):1321-1331. PubMed ID: 28176634 [TBL] [Abstract][Full Text] [Related]
30. Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer? Thillai K; Lam H; Sarker D; Wells CM Oncotarget; 2017 Feb; 8(8):14173-14191. PubMed ID: 27845911 [TBL] [Abstract][Full Text] [Related]
31. Apoptosis and expression of the Bcl-2 family of proteins and P53 in human pancreatic ductal adenocarcinoma. Chen D; Zheng X; Kang D; Yan B; Liu X; Gao Y; Zhang K Med Princ Pract; 2012; 21(1):68-73. PubMed ID: 22024503 [TBL] [Abstract][Full Text] [Related]
32. Advancement of NF-κB Signaling Pathway: A Novel Target in Pancreatic Cancer. Pramanik KC; Makena MR; Bhowmick K; Pandey MK Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30563089 [TBL] [Abstract][Full Text] [Related]
34. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Sebens Müerköster S; Werbing V; Sipos B; Debus MA; Witt M; Grossmann M; Leisner D; Kötteritzsch J; Kappes H; Klöppel G; Altevogt P; Fölsch UR; Schäfer H Oncogene; 2007 Apr; 26(19):2759-68. PubMed ID: 17086212 [TBL] [Abstract][Full Text] [Related]
35. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. Pu N; Gao S; Yin H; Li JA; Wu W; Fang Y; Zhang L; Rong Y; Xu X; Wang D; Kuang T; Jin D; Yu J; Lou W Cancer Lett; 2019 Sep; 460():42-53. PubMed ID: 31233838 [TBL] [Abstract][Full Text] [Related]
36. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Fritsche P; Seidler B; Schüler S; Schnieke A; Göttlicher M; Schmid RM; Saur D; Schneider G Gut; 2009 Oct; 58(10):1399-409. PubMed ID: 19528037 [TBL] [Abstract][Full Text] [Related]
37. Pancreatic Adenocarcinoma Therapeutics Targeting RTK and TGF Beta Receptor. Yang HH; Liu JW; Lee JH; Harn HJ; Chiou TW Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360896 [TBL] [Abstract][Full Text] [Related]
38. The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells. Giannuzzo A; Pedersen SF; Novak I Mol Cancer; 2015 Nov; 14():203. PubMed ID: 26607222 [TBL] [Abstract][Full Text] [Related]
39. HIF-2α regulates non-canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma. Li W; Chen C; Zhao X; Ye H; Zhao Y; Fu Z; Pan W; Zheng S; Wei L; Nong T; Li Z; Chen R J Cell Mol Med; 2017 Nov; 21(11):2896-2908. PubMed ID: 28544376 [TBL] [Abstract][Full Text] [Related]